Panbela Therapeutics (PBLA) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 08, 2021
Document Information [Line Items]
Entity Central Index Key	0001029125
Entity Registrant Name	Panbela Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-39468
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0543922
Entity Address, Address Line One	712 Vista Blvd #305
Entity Address, City or Town	Waconia
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55387
City Area Code	952
Local Phone Number	479-1196
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	PBLA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		13,434,152

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 14,072	$ 9,022
Prepaid expenses and other current assets	118	412
Income tax receivable	559	323
Total current assets	14,749	9,757
Other noncurrent assets	53	56
Total assets	14,802	9,813
Current liabilities:
Accounts payable	796	554
Accrued expenses	543	811
Total current liabilities	1,339	1,365
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of September 30, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 13,434,152 and 9,664,427 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	13	10
Additional paid-in capital	65,891	54,848
Accumulated deficit	(52,624)	(46,026)
Accumulated comprehensive income (loss)	183	(384)
Total stockholders' equity	13,463	8,448
Total liabilities and stockholders' equity	$ 14,802	$ 9,813

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	13,434,152	9,664,427
Common stock, shares outstanding (in shares)	13,434,152	9,664,427

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
General and administrative	$ 924	$ 1,223	$ 3,316	$ 2,348
Research and development	1,286	773	3,383	1,805
Operating loss	(2,210)	(1,996)	(6,699)	(4,153)
Other (expense) income:
Interest income	1	0	1	0
Interest expense	(2)	(3)	(9)	(12)
Other (expense) income	(335)	239	(611)	55
Total other (expense) income	(336)	236	(619)	43
Loss before income tax benefit	(2,546)	(1,760)	(7,318)	(4,110)
Income tax benefit	404	89	721	222
Net loss	(2,142)	(1,671)	(6,597)	(3,888)
Foreign currency translation adjustment	327	(246)	566	(164)
Comprehensive loss	$ (1,815)	$ (1,917)	$ (6,031)	$ (4,052)
Basic and diluted net loss per share (in dollars per share)	$ (0.16)	$ (0.21)	$ (0.59)	$ (0.55)
Weighted average shares outstanding - basic and diluted (in shares)	13,285,223	7,888,609	11,122,725	7,085,326

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]AOCI Attributable to Parent [Member]	Private Placement [Member]	Underwritten Public Offering [Member]Common Stock [Member]	Underwritten Public Offering [Member]Additional Paid-in Capital [Member]	Underwritten Public Offering [Member]Retained Earnings [Member]	Underwritten Public Offering [Member]AOCI Attributable to Parent [Member]	Underwritten Public Offering [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2019											6,631,000
Balances at Dec. 31, 2019											$ 7	$ 42,331	$ (41,258)	$ 305	$ 1,385
Stock-based compensation											0	112	0	0	112
Net loss											0	0	(1,798)	0	(1,798)
Foreign currency translation adjustment											0	0	0	797	797
Warrants issued for future services											$ 0	228	0	0	228
Balances (in shares) at Mar. 31, 2020											6,631,000
Balances at Mar. 31, 2020											$ 7	42,671	(43,056)	1,102	724
Balances (in shares) at Dec. 31, 2019											6,631,000
Balances at Dec. 31, 2019											$ 7	42,331	(41,258)	305	1,385
Net loss															(3,888)
Foreign currency translation adjustment															(164)
Balances (in shares) at Sep. 30, 2020											9,649,000
Balances at Sep. 30, 2020											$ 10	54,544	(45,146)	141	9,549
Balances (in shares) at Mar. 31, 2020											6,631,000
Balances at Mar. 31, 2020											$ 7	42,671	(43,056)	1,102	724
Stock-based compensation											0	264	0	0	264
Net loss											0	0	(419)	0	(419)
Foreign currency translation adjustment											$ 0	0	0	(715)	(715)
Public offering of common stock (in shares)	437,000
Public offering of common stock	$ 0	$ 1,746	$ 0	$ 0	$ 1,746
Balances (in shares) at Jun. 30, 2020											7,068,000
Balances at Jun. 30, 2020											$ 7	44,681	(43,475)	387	1,600
Warrants exercised for cash (in shares)											28,000
Warrants exercised for cash											$ 0	52	0	0	52
Warrants exercised net cashless (in shares)											8,000
Warrants exercised net cashless											$ 0	0	0	0	0
Stock-based compensation											0	593	0	0	593
Net loss											0	0	(1,671)	0	(1,671)
Foreign currency translation adjustment											$ 0	0	0	(246)	(246)
Public offering of common stock (in shares)						2,545,000
Public offering of common stock						$ 3	$ 9,218	$ 0	$ 0	$ 9,221
Balances (in shares) at Sep. 30, 2020											9,649,000
Balances at Sep. 30, 2020											$ 10	54,544	(45,146)	141	9,549
Balances (in shares) at Dec. 31, 2020											9,664,000
Balances at Dec. 31, 2020											$ 10	54,848	(46,026)	(384)	8,448
Warrants exercised for cash (in shares)											229,000
Warrants exercised for cash											$ 0	1,042	0	0	1,042
Warrants exercised net cashless (in shares)											189,000
Warrants exercised net cashless											$ 0	0	0	0	0
Vested restricted stock units (in shares)											7,000
Vested restricted stock units											$ 0	0	0	0	0
Stock-based compensation											0	252	0	0	252
Net loss											0	0	(2,257)	0	(2,257)
Foreign currency translation adjustment											$ 0	0	0	99	99
Balances (in shares) at Mar. 31, 2021											10,089,000
Balances at Mar. 31, 2021											$ 10	56,142	(48,283)	(285)	7,584
Balances (in shares) at Dec. 31, 2020											9,664,000
Balances at Dec. 31, 2020											$ 10	54,848	(46,026)	(384)	$ 8,448
Warrants exercised for cash (in shares)															228,939
Warrants exercised net cashless (in shares)															190,588
Net loss															$ (6,597)
Foreign currency translation adjustment															566
Balances (in shares) at Sep. 30, 2021											13,434,000
Balances at Sep. 30, 2021											$ 13	65,891	(52,624)	183	13,463
Balances (in shares) at Mar. 31, 2021											10,089,000
Balances at Mar. 31, 2021											$ 10	56,142	(48,283)	(285)	7,584
Warrants exercised net cashless (in shares)											2,000
Warrants exercised net cashless											$ 0	0	0	0	0
Vested restricted stock units (in shares)											4,000
Vested restricted stock units											$ 0	0	0	0	0
Stock-based compensation											0	363	0	0	363
Net loss											0	0	(2,199)	0	(2,199)
Foreign currency translation adjustment											$ 0	0	0	141	141
Balances (in shares) at Jun. 30, 2021											10,095,000
Balances at Jun. 30, 2021											$ 10	56,505	(50,482)	(144)	5,889
Vested restricted stock units (in shares)											6,000
Vested restricted stock units											$ 0	0	0	0	0
Stock-based compensation											0	336	0	0	336
Net loss											0	0	(2,142)	0	(2,142)
Foreign currency translation adjustment											$ 0	0	0	327	327
Public offering of common stock (in shares)											3,333,000
Public offering of common stock											$ 3	9,050			9,053
Balances (in shares) at Sep. 30, 2021											13,434,000
Balances at Sep. 30, 2021											$ 13	$ 65,891	$ (52,624)	$ 183	$ 13,463

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (6,597)	$ (3,888)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	951	969
Changes in operating assets and liabilities:
Income tax receivable	(201)	133
Prepaid expenses and other current assets	221	64
Accounts payable	873	(347)
Accrued liabilities	(264)	328
Net cash used in operating activities	(5,017)	(2,741)
Cash flows from financing activities:
Proceeds from public offering of common stock net of underwriters discount and offering costs of $946	9,053
Proceeds from sale of common stock and warrants net of offering costs of $2		1,746
Proceeds from exercise of stock purchase warrants	1,042	52
Proceeds from paycheck protection loan	0	103
Repayments of term debt	0	(81)
Net cash provided by financing activities	10,095	11,155
Effect of exchange rate changes on cash and cash equivalents	(28)	7
Net change in cash and cash equivalents	5,050	8,421
Cash and cash equivalents at beginning of period	9,022	2,449
Cash and cash equivalents at end of period	14,072	10,870
Supplemental disclosure of cash flow information:
Cash paid during period for interest	9	5
Supplemental disclosure of non-cash transactions:
Warrants issued for future services	0	228
Warrants issued to underwriter	0	353
Amortization of warrants as offering costs	$ 0	114
Underwritten Public Offering [Member]
Cash flows from financing activities:
Proceeds from public offering of common stock and warrants net of underwriters discount and offering costs of $1,165		$ 9,335

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Proceeds from public offering of common stock, issuance costs	$ 946	$ 1,165
Private Placement [Member]
Proceeds from public offering of common stock, issuance costs		$ 2

Note 1 - Business

Note 1 - Business	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Panbela Therapeutics, Inc. and its wholly-owned subsidiary Panbela Therapeutics Pty Ltd (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for the treatment of patients with pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP- 101,

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Nature of Operations [Text Block]	2. Risks and Uncertainties The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may We have incurred losses of $52.6 million since our inception in 2011. nine September 30, 2021, 101, September 30, 2021, The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed not 2020 March 25, 2021. 101 101 4 September 2021 18 19” 19, 2020 first 2021 second September 30, 2021 19 19 2020 19. No 19 December 2020. 2021, no no

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	3. Basis of Presentation We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 X not December 31. December 31, 2020, not 10 may not

Note 4 - Liquidity and Business

Note 4 - Liquidity and Business Plan	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	4. Liquidity and Business Plan On July 2, 2021, Between February 5 March 23, 2021, On September 1, 2020, nine September 30, 2020 We will need to raise additional capital to fully fund the randomized clinical trial set to begin enrollment at the end of 2021.Our 101 101 not not There can be no

Note 5 - Summary of Significant

Note 5 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	5. Summary of Significant Accounting Policies Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties with the ongoing pandemic and control responses. Research and development costs Research and development costs include expenses incurred in the conduct of our second 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not Foreign currency translation adjustments The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity. During the three nine September 30, 2021, 2020, Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include outstanding common stock options, and warrants, have not The following table sets forth the potential shares of common stock that were not September 30, 2021 2020 Employee and non-employee stock options 2,489,136 2,170,459 Resticted stock units 16,185 - Common stock issuable under common stock purchase warrants 5,109,501 6,571,468 7,614,822 8,741,927

Note 6 - Stockholders' Equity

Note 6 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. Stockholders Equity Public offering of common stock On July 2, 2021, Warrants exercised and expired During the nine September 30, 2021, nine September 30, 2021. nine September 30, 2021. Public offering of common stock and warrants On September 1, 2020, five September 30, 2021. Shares reserved The following shares of common stock were reserved for future issuance as of date indicated: September 30, 2021 Stock options outstanding 2,489,136 Restricted stock units 16,185 Shares available for grant under equity incentive plan 1,328,363 Common shares issuable under outstanding common stock purchase warrants 5,109,501 8,943,185

Note 7 - Stock-based Compensati

Note 7 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	7. Stock-based Compensation 2016 The Panbela Therapeutics, Inc. 2016 “2016 March 2016 May 2016. 2016 2016 no 2016 ten September 30, 2021, one 2016 2011 Our Board of Directors ceased making awards under the Panbela Therapeutics, Inc. 2011 “2011 2016 May 2016. 2011 September 30, 2021, 2011 Stock-based Compensation Expense General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through September 30, 2021, September 30, 2021. Stock-based compensation expense for each of the periods presented is as follows (in thousands): Nine Months Ended September 30, 2021 2020 General and Administrative $ 798 $ 860 Research and Development 153 109 $ 951 $ 969 Information about stock options outstanding, vested and expected to vest as of September 30, 2021, Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $0.875 - $1.10 22,000 1.17 $ 1.02 22,000 1.17 $2.26 - $2.50 79,225 7.81 $ 2.31 22,000 2.45 $2.95 - $4.17 1,207,940 7.70 $ 3.41 707,535 6.41 $4.50 - $8.10 687,100 6.94 $ 6.13 609,600 6.72 $9.99 - $10.10 266,048 8.18 $ 9.99 160,024 7.78 $15.10 - 226,823 4.47 $ 15.10 226,823 4.47 Totals 2,489,136 7.49 $ 5.88 1,747,982 6.36 Key assumptions The estimated grant-date fair values of the stock options were calculated using the Black-Scholes valuation model, based on the following assumptions for the nine September 30, 2021: 2021 Common stock fair value $2.26 to $4.17 Risk-free interest rate 0.79% to 1.08% Expected dividend yield 0 Expected Option life (yrs) 5.30 to 5.75 Expected stock price volatility 90%

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties with the ongoing pandemic and control responses.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development costs include expenses incurred in the conduct of our second 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no
Share-based Payment Arrangement [Policy Text Block]	Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation adjustments The functional currency of Panbela Therapeutics Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Panbela Therapeutics Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity. During the three nine September 30, 2021, 2020,
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation.
Earnings Per Share, Policy [Policy Text Block]	Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include outstanding common stock options, and warrants, have not The following table sets forth the potential shares of common stock that were not September 30, 2021 2020 Employee and non-employee stock options 2,489,136 2,170,459 Resticted stock units 16,185 - Common stock issuable under common stock purchase warrants 5,109,501 6,571,468 7,614,822 8,741,927

Note 5 - Summary of Significa_2

Note 5 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2021 2020 Employee and non-employee stock options 2,489,136 2,170,459 Resticted stock units 16,185 - Common stock issuable under common stock purchase warrants 5,109,501 6,571,468 7,614,822 8,741,927

Note 6 - Stockholders' Equity (

Note 6 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	September 30, 2021 Stock options outstanding 2,489,136 Restricted stock units 16,185 Shares available for grant under equity incentive plan 1,328,363 Common shares issuable under outstanding common stock purchase warrants 5,109,501 8,943,185

Note 7 - Stock-based Compensa_2

Note 7 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Nine Months Ended September 30, 2021 2020 General and Administrative $ 798 $ 860 Research and Development 153 109 $ 951 $ 969
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding, Vested and Expected to Vest Options Vested and Exercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Exercisable Weighted Average Remaining Contractual Life (Years) $0.875 - $1.10 22,000 1.17 $ 1.02 22,000 1.17 $2.26 - $2.50 79,225 7.81 $ 2.31 22,000 2.45 $2.95 - $4.17 1,207,940 7.70 $ 3.41 707,535 6.41 $4.50 - $8.10 687,100 6.94 $ 6.13 609,600 6.72 $9.99 - $10.10 266,048 8.18 $ 9.99 160,024 7.78 $15.10 - 226,823 4.47 $ 15.10 226,823 4.47 Totals 2,489,136 7.49 $ 5.88 1,747,982 6.36
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2021 Common stock fair value $2.26 to $4.17 Risk-free interest rate 0.79% to 1.08% Expected dividend yield 0 Expected Option life (yrs) 5.30 to 5.75 Expected stock price volatility 90%

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Retained Earnings (Accumulated Deficit), Ending Balance	$ (52,624)						$ (52,624)		$ (46,026)
Net Income (Loss) Attributable to Parent, Total	(2,142)	$ (2,199)	$ (2,257)	$ (1,671)	$ (419)	$ (1,798)	(6,597)	$ (3,888)
Net Cash Provided by (Used in) Operating Activities, Total							(5,017)	(2,741)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	14,072						14,072		9,022
Working Capital	13,400						13,400
Stockholders' Equity Attributable to Parent, Ending Balance	$ 13,463	$ 5,889	$ 7,584	$ 9,549	$ 1,600	$ 724	$ 13,463	$ 9,549	$ 8,448	$ 1,385

Note 4 - Liquidity and Busine_2

Note 4 - Liquidity and Business Plan (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 02, 2021	Sep. 01, 2020	Mar. 23, 2021	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Proceeds from Issuance of Common Stock, Net					$ 9,053
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)			228,938		228,939
Proceeds from Warrant Exercises			$ 1,000		$ 1,042	$ 52
Proceeds from Issuance of Private Placement						1,746
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,333,334	2,545,454
Shares Issued, Price Per Share (in dollars per share)	$ 3
Proceeds from Issuance of Common Stock, Net	$ 9,100
Proceeds from Issuance of Common Stock, Net		$ 9,300				$ 9,335
Private Placement [Member]
Proceeds from Issuance of Private Placement				$ 1,700

Note 5 - Summary of Significa_3

Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Anti-dilutive securities (in shares)	7,614,822	8,741,927
Share-based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	2,489,136	2,170,459
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)	16,185	0
Warrant [Member]
Anti-dilutive securities (in shares)	5,109,501	6,571,468

Note 6 - Stockholders' Equity_2

Note 6 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 02, 2021	Sep. 01, 2020	Mar. 23, 2021	Sep. 30, 2021	Sep. 30, 2020
Proceeds from Issuance of Common Stock, Net				$ 9,053
Stock Issued During Period, Shares, Exercise of Warrants for Cash (in shares)			228,938	228,939
Proceeds from Warrant Exercises			$ 1,000	$ 1,042	$ 52
Stock Issued During Period, Shares, Cashless Exercise of Warrants (in shares)				190,588
Class of Warrant or Right, Exercised During Period (in shares)				536,140
Warrants With Exercise Price of $5.00 [Member]
Class of Warrants or Rights, Cancelled During the Period (in shares)				573,339
Class of Warrant or Right, Cancelled During Period, Exercise Price (in dollars per share)				$ 5
Warrants With Exercise Price of $15.00 [Member]
Class of Warrants or Rights, Cancelled During the Period (in shares)				108,550
Class of Warrant or Right, Cancelled During Period, Exercise Price (in dollars per share)				$ 15
Underwritten Warrants [Member]
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 4.54
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				2,306,516
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,333,334	2,545,454
Shares Issued, Price Per Share (in dollars per share)	$ 3
Proceeds from Issuance of Common Stock	$ 10,000
Proceeds from Issuance of Common Stock, Net	$ 9,100
Proceeds from Issuance or Sale of Equity, Total		$ 10,500
Proceeds from Issuance of Common Stock, Net		$ 9,300			$ 9,335

Note 6 - Stockholders' Equity -

Note 6 - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)	Sep. 30, 2021shares
Shares reserved (in shares)	8,943,185
Warrant [Member]
Shares reserved (in shares)	5,109,501
Share-based Payment Arrangement, Option [Member]
Shares reserved (in shares)	2,489,136
Restricted Stock Units (RSUs) [Member]
Shares reserved (in shares)	16,185
Shares Available for Grant Under Equity Incentive Plan [Member]
Shares reserved (in shares)	1,328,363

Note 7 - Stock-based Compensa_3

Note 7 - Stock-based Compensation (Details Textual) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)shares
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $	$ 1.9
Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	2,257,136
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	1,328,363
Panbela Therapeutics, Inc. 2016 Omnibus Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	16,185
Panbela Therapeutics, Inc. 2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	232,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	3 years 2 months 12 days

Note 7 - Stock-based Compensa_4

Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based compensation expense	$ 951	$ 969
General and Administrative Expense [Member]
Share-based compensation expense	798	860
Research and Development Expense [Member]
Share-based compensation expense	$ 153	$ 109

Note 7 - Stock-based Compensa_5

Note 7 - Stock-based Compensation - Options Outstanding (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Options outstanding (in shares) | shares	2,489,136
Options outstanding, weighted average remaining contractual life (Year)	7 years 5 months 26 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.88
Options exercisable (in shares) | shares	1,747,982
Options excercisable, weighted average remaining contractual life (Year)	6 years 4 months 9 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 0.875
Per share exercise price, upper limit (in dollars per share)	$ 1.10
Options outstanding (in shares) | shares	22,000
Options outstanding, weighted average remaining contractual life (Year)	1 year 2 months 1 day
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.02
Options exercisable (in shares) | shares	22,000
Options excercisable, weighted average remaining contractual life (Year)	1 year 2 months 1 day
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.26
Per share exercise price, upper limit (in dollars per share)	$ 2.50
Options outstanding (in shares) | shares	79,225
Options outstanding, weighted average remaining contractual life (Year)	7 years 9 months 21 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.31
Options exercisable (in shares) | shares	22,000
Options excercisable, weighted average remaining contractual life (Year)	2 years 5 months 12 days
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.95
Per share exercise price, upper limit (in dollars per share)	$ 4.17
Options outstanding (in shares) | shares	1,207,940
Options outstanding, weighted average remaining contractual life (Year)	7 years 8 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.41
Options exercisable (in shares) | shares	707,535
Options excercisable, weighted average remaining contractual life (Year)	6 years 4 months 28 days
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 4.50
Per share exercise price, upper limit (in dollars per share)	$ 8.10
Options outstanding (in shares) | shares	687,100
Options outstanding, weighted average remaining contractual life (Year)	6 years 11 months 8 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.13
Options exercisable (in shares) | shares	609,600
Options excercisable, weighted average remaining contractual life (Year)	6 years 8 months 19 days
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 9.99
Per share exercise price, upper limit (in dollars per share)	$ 10.10
Options outstanding (in shares) | shares	266,048
Options outstanding, weighted average remaining contractual life (Year)	8 years 2 months 4 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.99
Options exercisable (in shares) | shares	160,024
Options excercisable, weighted average remaining contractual life (Year)	7 years 9 months 10 days
Exercise Price Range 6 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 15.10
Options outstanding (in shares) | shares	226,823
Options outstanding, weighted average remaining contractual life (Year)	4 years 5 months 19 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.10
Options exercisable (in shares) | shares	226,823
Options excercisable, weighted average remaining contractual life (Year)	4 years 5 months 19 days

Note 7 - Stock-based Compensa_6

Note 7 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details)	9 Months Ended
	Sep. 30, 2021$ / shares
Expected dividend yield	0.00%
Expected stock price volatility	90.00%
Minimum [Member]
Common stock fair value (in dollars per share)	$ 2.26
Risk-free interest rate	0.79%
Expected Option life (yrs) (Year)	5 years 3 months 18 days
Maximum [Member]
Common stock fair value (in dollars per share)	$ 4.17
Risk-free interest rate	1.08%
Expected Option life (yrs) (Year)	5 years 9 months